The new supply agreement relates to Dyloject, Javelin’s proprietary injectable diclofenac product currently marketed in the UK and in the second of two pivotal trials in the US, for acute post-operative pain.
The expanded relationship provides additional manufacturing capacity for Dyloject, principally for distribution in the EU, and builds on the existing manufacturing agreement executed between Javelin and Baxter for the US.
Martin Driscoll, CEO of Javelin, said: “We are pleased to strengthen our relationship with Baxter. This expanded commercial supply agreement will provide increased capacity for Dyloject in Europe as we grow sales of the product in the UK and prepare for the anticipated launch of the product in multiple European countries in the near future.”